New and Emerging Agents in the Management of Lipodystrophy in HIV-infected Patients

Overview

Journal HIV AIDS (Auckl)

Publisher Dove Medical Press

Specialty Infectious Diseases

Date 2011 Nov 19

PMID 22096395

Citations 4

Authors

Eric Bonnet

Affiliations

Soon will be listed here.

Abstract

Lipodystrophy remains a major long-term complication in human immunodeficiency virus-infected patients under antiretroviral (ARV) therapy. Patients may present with lipoatrophy or lipohypertrophy or both. The choice of treatments to improve fat redistribution depends on the form of lipodystrophy and its duration. Measures known to improve lipoatrophy are switches in ARV therapy (stavudine or zidovudine to abacavir or tenofovir) and filling interventions. Pioglitazone may be added to these measures, although any benefits appear small. Uridine and leptin were found to be disappointing so far. Regarding lipohypertrophy, diet and exercise, recombinant human growth hormone, and metformin may reduce visceral fat, but may worsen subcutaneous lipoatrophy. Surgical therapy may be required. Attractive pharmacologic treatments include growth hormone-releasing factor and leptin. Adiponectin and adiponectin receptors are promising therapeutic targets to explore.

Citing Articles

Metformin Treatment Leads to Increased HIV Transcription and Gene Expression through Increased CREB Phosphorylation and Recruitment to the HIV LTR Promoter.

Rezaei S, Timani K, He J Aging Dis. 2023; 15(2):831-850.

PMID: 37450926 PMC: 10917544. DOI: 10.14336/AD.2023.0705.

Unilateral Limb Thinning -Thinking Out of the Box.

Venkatraman C, Subramanian S, Abraham D, Vellaichamy K Ann Indian Acad Neurol. 2018; 21(1):74-76.

PMID: 29720803 PMC: 5909151. DOI: 10.4103/aian.AIAN_416_17.

Leptin, Adiponectin and Cognition in Middle-aged HIV-infected and Uninfected Women. The Brooklyn Women's Interagency HIV Study.

Gustafson D, Mielke M, Keating S, Holman S, Minkoff H, Crystal H J Gerontol Geriatr Res. 2016; 4(5).

PMID: 27536467 PMC: 4984413. DOI: 10.4172/2167-7182.1000240.

Focal lipoatrophy of face: a rare esthetic complaint.

Anbarasi K, Sathasivasubramanian S, Krithika C, Venkatasai P J Clin Imaging Sci. 2012; 2:14.

PMID: 22530185 PMC: 3329066. DOI: 10.4103/2156-7514.94229.

References

Haubrich R, Riddler S, DiRienzo A, Komarow L, Powderly W, Klingman K . Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009; 23(9):1109-18. PMC: 2739977. DOI: 10.1097/QAD.0b013e32832b4377. View

Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker J . Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002; 16(18):2447-54. DOI: 10.1097/00002030-200212060-00010. View

Addy C, Gavrila A, Tsiodras S, Brodovicz K, Karchmer A, Mantzoros C . Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab. 2003; 88(2):627-36. DOI: 10.1210/jc.2002-020795. View

Mallon P, Miller J, Kovacic J, Kent-Hughes J, Norris R, Samaras K . Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study. AIDS. 2006; 20(7):1003-10. DOI: 10.1097/01.aids.0000222072.37749.5a. View

Rajagopalan R, Laitinen D, Dietz B . Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy. AIDS Care. 2008; 20(10):1197-201. PMC: 3320100. DOI: 10.1080/09540120801926993. View

Guaraldi G, Murri R, Orlando G, Giovanardi C, Squillace N, Vandelli M . Severity of lipodystrophy is associated with decreased health-related quality of life. AIDS Patient Care STDS. 2008; 22(7):577-85. PMC: 2929152. DOI: 10.1089/apc.2007.0173. View

Sturm L, Cooter R, Mutimer K, Graham J, Maddern G . A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy. AIDS Patient Care STDS. 2009; 23(9):699-714. DOI: 10.1089/apc.2008.0230. View

Wanke C, Polsky B, Kotler D . Guidelines for using body composition measurement in patients with human immunodeficiency virus infection. AIDS Patient Care STDS. 2002; 16(8):375-88. DOI: 10.1089/10872910260196404. View

Negredo E, Higueras C, Adell X, Martinez J, Martinez E, Puig J . Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances. AIDS Patient Care STDS. 2006; 20(12):829-37. DOI: 10.1089/apc.2006.20.829. View

10.

Engelson E, Agin D, Kenya S, Werber-Zion G, Luty B, Albu J . Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism. 2006; 55(10):1327-36. DOI: 10.1016/j.metabol.2006.05.018. View

11.

Ranade K, Geese W, Noor M, Flint O, Tebas P, Mulligan K . Genetic analysis implicates resistin in HIV lipodystrophy. AIDS. 2008; 22(13):1561-8. PMC: 4410015. DOI: 10.1097/QAD.0b013e32830a9886. View

12.

Engelson E, Glesby M, Mendez D, Albu J, Wang J, Heymsfield S . Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr. 2002; 30(4):379-91. DOI: 10.1097/00042560-200208010-00002. View

13.

Vigouroux C, Maachi M, Nguyen T, Coussieu C, Gharakhanian S, Funahashi T . Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS. 2003; 17(10):1503-11. DOI: 10.1097/00002030-200307040-00011. View

14.

Martin A, Smith D, Carr A, Ringland C, Amin J, Emery S . Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004; 18(7):1029-36. DOI: 10.1097/00002030-200404300-00011. View

15.

Connolly N, Manders E, Riddler S . Suction-assisted lipectomy for lipodystrophy. AIDS Res Hum Retroviruses. 2004; 20(8):813-5. DOI: 10.1089/0889222041725208. View

16.

Saves M, Raffi F, Capeau J, Rozenbaum W, Ragnaud J, Perronne C . Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002; 34(10):1396-405. DOI: 10.1086/339866. View

17.

Chen C, Cheng Y . Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol. 1991; 39(5):625-8. View

18.

Law M, Puls R, Cheng A, Cooper D, Carr A . Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults. Antivir Ther. 2006; 11(2):179-86. View

19.

BENSON J, McGhee K, Coplan P, Grunfeld C, Robertson M, Brodovicz K . Fat redistribution in indinavir-treated patients with HIV infection: A review of postmarketing cases. J Acquir Immune Defic Syndr. 2000; 25(2):130-9. DOI: 10.1097/00042560-200010010-00007. View

20.

Bogner J, Vielhauer V, Beckmann R, Michl G, Wille L, Salzberger B . Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001; 27(3):237-44. DOI: 10.1097/00126334-200107010-00004. View